Hyperlipidemia in patients with chronic renal disease

American Journal of Kidney Diseases

Volumn 32, Issue 5 SUPPL. 3, 1998, Pages

  Kasiske, Bertram L ^a  

^a HENNEPIN COUNTY MEDICAL CENTER   (United States)

Author keywords

Antilipemic agents; Hyperlipidemia; Kidney failure; Myocardial ischemia

Indexed keywords

ANTILIPEMIC AGENT; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR;

CHOLESTEROL BLOOD LEVEL; CHRONIC KIDNEY DISEASE; CHRONIC KIDNEY FAILURE; DISEASE ASSOCIATION; HUMAN; HYPERLIPIDEMIA; NEPHROTIC SYNDROME; PRACTICE GUIDELINE; REVIEW;

EID: 0031733360     PISSN: 02726386     EISSN: None     Source Type: Journal    
DOI: 10.1053/ajkd.1998.v32.pm9820472     Document Type: Review

References (117)

1. Expert Panel on Detection Evaluation and Treatment of High Blood Cholesterol in Adults: Summary of the Second Report of the National Cholesterol Education Program (NCEP) (Adult Treatment Panel II). JAMA 269:3015-3023, 1993
2. Jungst D, Caselmann H, Kutschera P, Weisweiler P: Relation of hyperlipidemia in serum and loss of high density lipoproteins in urine in the nephrotic syndrome. Clin Chim Acta 168:159-167, 1987
3. Nayak SS, Bhaskaranand N, Kamath KS, Baliga M, Venkatesh A, Aroor AR: Serum apolipoproteins A and B, lecithin: Cholesterol acyl transferase activities and urinary cholesterol levels in nephrotic syndrome patients before and during steroid treatment. Nephron 54:234-239, 1990
4. Takegoshi T, Kitoh C, Haba T, Hirai J, Wakasugi T, Saga T, Yamazaki Y, Mabuchi H: A study of the clinical significance of lipoprotein(a) in nephrotic syndrome. Jpn J Med 30:21-25, 1991
5. Clemens MR, Bursa-Zanetti Z: Lipid abnormalities and peroxidation of erythrocytes in nephrotic syndrome. Nephron 53:325-329, 1989
6. Joven J, Rubiës-Prat J, Espinel E, Ras MR, Piera L: High-density lipoproteins in untreated idiopathic nephrotic syndrome without renal failure. Nephrol Dial Transplant 2:149-153, 1987
7. Nayak SS, Bhaskaranand N, Baliga M, Venkatesh A, Rao PV, Aroor AR: Serum HDL-cholesterol & urinary cholesterol in nephrotic syndrome. Indian J Med Res 88: 150-155, 1988
8. Kaysen GA, Gambertoglio J, Felts J, Hutchison FN: Albumin synthesis, albuminuria and hyperlipemia in nephrotic patients. Kidney Int 31:1368-1376, 1987
9. Läszlö A, Havass Z, Joö I, Bodrogi T, Turi S: [Lipid and lipoprotein studies in nephrotic syndrome cases in childhood]. Kinderarztl Prax 53:199-203, 1985
10. Ohta T, Matsuda I: Lipid and apolipoprotein levels in patients with nephrotic syndrome. Clin Chim Acta 117:133-143, 1981
11. Michaeli J, Bar-On H, Shafrir E: Lipoprotein profiles in a heterogeneous group of patients with nephrotic syndrome. Isr J Med Sci 17:1001-1008, 1981
12. Chan MK, Persaud JW, Ramdial L, Varghese Z, Sweny P, Moorhead JF: Hyperlipidaemia in untreated nephrotic syndrome, increased production or decreased removal? Clin Chim Acta 117:317-323, 1981
13. Cohen SL, Cramp DG, Lewis AD, Tickner TR: The mechanism of hyperlipidaemia in nephrotic syndrome - Role of low albumin and the LCAT reaction. Clin Chim Acta 104:393-400, 1980
14. Kashyap ML, Srivastava LS, Hynd BA, Brady D, Perisutti G, Glueck CJ, Gartside PS: Apolipoprotein CII and lipoprotein lipase in human nephrotic syndrome. Atherosclerosis 35:29-40, 1980
15. Gherardi E, Rota E, Calandra S, Genova R, Tamborino A: Relationship among the concentrations of serum lipoproteins and changes in their chemical composition in patients with untreated nephrotic syndrome. Eur J Clin Invest 7:563-570, 1977
16. Chopra JS, Mallick NP: Hyperlipoproteinaemias in nephrotic syndrome. Lancet 1:317-321, 1971
17. Faucher C, Doucet C, Baumelou A, Chapman JJC, Thillet J: Elevated lipoprotein(a) levels in primary nephrotic syndrome. Am J Kidney Dis 22:808-813, 1993
18. Thomas ME, Freestone A, Varghese Z, Persaud JW, Moorhead JF: Lipoprotein(a) in patients with proteinuria. Nephrol Dial Transplant 7:597-601, 1992
19. Wanner C, Rader D, Bartens W, Krämer J, Brewer HB, Schollmeyer P, Wieland H: Elevated plasma lipoprotein (a) in patients with the nephrotic syndrome. Ann Intern Med 119:263-269, 1993
20. Stenvinkel P, Berglund L, Heimbürger O, Pettersson E, Alvestrand A: Lipoprotein(a) in nephrotic syndrome. Kidney Int 44:1116-1123, 1993
21. Joven J, Villabona C, Vilella E: Pattern of hyperlipoproteinemia in human nephrotic syndrome: influence of renal failure and diabetes mellitus. Nephron 64:565-569, 1993
22. Appel GB, Blum CB, Chien S, Koopman MG, Appel AS: The hyperlipidemia of the nephrotic syndrome. Relation to plasma albumin concentration, oncotic pressure, and viscosity. N Engl J Med 312:1544-1548, 1985
23. Ordoñez JD, Hiatt RA, Killebrew EJ, Fireman BH: The increased risk of coronary artery disease associated with nephrotic syndrome. Kidney Int 44:638-642, 1993
24. Camejo G, Ripra G, Lee M, Lopez F: Lipoprotein structural abnormalities in chronic renal failure with and without hemodialysis. Biomed Biochim Acta 47:239-245, 1988
25. Papadopoulou ZL, Sandler P, Tina LU, Jose PA, Calcagno PL: Hyperlipidemia in children with chronic renal insufficiency. Pediatr Res 15:887-891, 1981
26. Abdullah MS, Kyobe J, Karimi M: Lipid profile in Africans with renal failure. East Afr Med J 56:45-48, 1979
27. Brons M, Christensen NC, Horder M: Hyperlipoproteinemia in patients with chronic renal failure. Acta Med Scand 192:119-123, 1972
28. Graf H, Stummvoll HK, Muller MM: [High-density-lipoprotein and renal insufficiency (author's transl)]. Wien Klin Wochenschr 94:39-41, 1982
29. Cianciaruso B, Memoli B, Lus G, Auciello A, Andreucci VE, Spanö A, Di Fraia G, Oriente P: Lipid abnormalities in patients with different degrees of chronic renal failure. Contrib Nephrol 41:438-440, 1984
30. Bagdade JD: Uremic lipemia. An unrecognized abnormality in triglyceride production and removal. Arch Intern Med 126:875-881, 1970
31. Verschoor L, Lammers R, Birkenhäger JC: Triglyceride turnover in severe chronic non-nephrotic renal failure. Metabolism 27:879-883, 1978
32. Schäfer B, Kluthe R: [Lipid metabolism in patients with chronic renal insufficiency under conservative treatment (author's transl)]. Med Klin 69:577-581, 1974
33. Oida K, Takai H, Maeda H, Takahashi S, Shimada A, Suzuki J, Tamai T, Nakai T, Miyabo S: Apolipoprotein(a) is present in urine and its excretion is decreased in patients with renal failure. Clin Chem 38:2244-2248, 1992
34. Attman PO, Alaupovic P: Lipid and apolipoprotein profiles of uremic dyslipoproteinemia - Relation to renal function and dialysis. Nephron 57:401-410, 1991
35. Grützmacher P, März W, Peschke B, Gross W, Schoeppe W: Lipoproteins and apolipoproteins during the progression of chronic renal disease. Nephron 50:103-111, 1988
36. Arnadottir M, Thysell H, Nilsson-Ehle P: Serum lipoprotein (a) concentration is increased in moderate renal function. Nephron 72:712-713, 1996
37. Attman P-O, Nyberg G, William-Olsson T, Knight-Gibson C, Alaupovic P: Dyslipoproteinemia in diabetic renal failure. Kidney Int 42:1381-1389, 1992
38. Jungers P, Massy ZA, Nguyen Khoa T, Fumeron C, Labrunie M, Lacour B, Descamps-Latscha B, Man NK: Incidence and risk factors of atherosclerotic cardiovascular accidents in predialysis chronic renal failure patients: A prospective study. Nephrol Dial Transplant 12:2597-2602, 1997
39. Lee HS, Lee JS, Koh HI, Ko KW: Intraglomerular lipid deposition in routine biopsies. Clin Nephrol 36:67-75, 1991
40. Sato H, Suzuki S, Kobayashi H, Ogino S, Inomata A, Arakawa M: Immunohistological localization of apolipoproteins in the glomeruli in renal disease: Specifically apoB and apoE. Clin Nephrol 36:127-133, 1991
41. Sato H, Suzuki S, Ueno M, Shimada H, Karasawa R, Nishi S-I, Arakawa M: Localization of apolipoprotein(a) and B-100 in various renal diseases. Kidney Int 43:430-435, 1993
42. Schönholzer KW, Waldron M, Magil AB: Intraglomerular foam cells and human focal glomerulosclerosis. Nephron 62:130-136, 1992
43. Samuelsson O, Mulec H, Knight-Gibson C, Attman P-O, Kron B, Larsson R, Weiss L, Wedel H, Alaupovic P: Lipoprotein abnormalities are associated with increased rate of progression of human chronic renal insufficiency. Nephrol Dial Transplant 12:1908-1915, 1997
44. Hunsicker LG, Adler S, Caggiula A, England BK, Greene T, Kusek JW, Rogers NL, Teschan PE: Predictors of the progression of renal disease in the Modification of Diet in Renal Disease Study. Kidney Int 51:1908-1919, 1997
45. Krolewski AS, Warram JH, Christlieb AR: Hypercholesterolemia - A determinant of renal function loss and deaths in IDDM patients with nephropathy. Kidney Int. 45:S-125-S-131, 1994 (suppl 45)
46. Ravid M, Neumann L, Lishner M: Plasma lipids and the progression of nephropathy in diabetes mellitus type II: Effect of ACE inhibitors. Kidney Int 47:907-910, 1995
47. Horita K, Eto M, Makino I: Apolipoprotein E2, renal failure and lipid abnormalities in non-insulin-dependent diabetes mellitus. Atherosclerosis 107:203-211, 1994
48. Eto M, Horita K, Morikawa A, Nakata H, Okada M, Saito M, Nomura M, Abiko A, Iwashima Y, Ikoda A, Makino I: Increased frequency of apolipoprotein e2 allele in non-insulin dependent diabetic (NIDDM) patients with nephropathy. Clin Genet 48:288-292, 1995
49. Boize R, Benhamou P-Y, Corticelli P, Valenti K, Bosson J-L, Halimi S: ApoE polymorphism and albuminuria in diabetes mellitus: A role for LDL in the development of nephropathy in NIDDM? Nephrol Dial Transplant 13:72-75, 1998
50. Onuma T, Laffel LMB, Angelico C, Krolewski AS: Apolipoprotein E genotypes and risk of diabetic nephropathy. J Am Soc Nephrol 7:1075-1078, 1996
51. Scanferla F, Toffoletto PP, Roncali D, Bazzato G: Associated effect of hepatic hydroxymethylglutaryl coenzyme A reductase + angiotensin converting enzyme inhibitors on the progression of renal failure in hypertensive subjects. Am J Hypertens 4:868-868, 1991
52. Chan PC, Robinson JD, Yeung WC, Cheng IK, Yeung HW, Tsang MT: Lovastatin in glomerulonephritis patients with hyperlipidaemia and heavy proteinuria. Nephrol Dial Transplant 7:93-99, 1992
53. Chan PCK, Chan KW, Cheng IKP, Chan MK: Focal sclerosing glomerulopathy risk factors of progression and optimal mode of treatment. Int Urol Nephrol 23:619-629, 1991
54. Muso E, Yashiro M, Matsushima M, Yoshida H, Sawanishi K, Sasayama S: Does LDL-apheresis in steroid-resistant nephrotic syndrome affect prognosis? Nephrol Dial Transplant 9:257-264, 1994
55. Lam KSL, Cheng IKP, Janus ED, Pang RWC: Cholesterol-lowering therapy may retard the progression of diabetic nephropathy. Diabetologia 38:604-609, 1995
56. Nielsen S, Schmitz O, Moller N, Porksen N, Klausen IC, Alberti KG, Mogensen CE: Renal function and insulin sensitivity during simvastatin treatment in type 2 (non-insulin-dependent) diabetic patients with microalbuminuria. Diabetologia 36:1079-1079, 1993
57. Rayner BL, Byrne MJ, van Zyl Smit R: A prospective clinical trial comparing the treatment of idiopathic membranous nephropathy and nephrotic syndrome with simvastatin and diet, versus diet alone. Clin Nephrol 46:219-224, 1996
58. Nestel PJ, Fidge NH, Tan MH: Increased lipoprotein-remnant formation in chronic renal failure. N Engl J Med 307:329-333, 1982
59. Dieplinger H, Schoenfeld PY, Fielding CJ: Plasma cholesterol metabolism in end-stage renal disease. J Clin Invest 77:1071-1083, 1986
60. Bolzano K, Krempler F, Sandhofer F: Hepatic and extrahepatic triglyceride lipase activity in uraemic patients on chronic haemodialysis. Eur J Clin Invest 8:289-293, 1978
61. Cattran DC, Fenton SS, Wilson DR, Steiner G: Defective triglyceride removal in lipemia associated with peritoneal dialysis and haemodialysis. Ann Intern Med 85:29-33, 1976
62. Wada M, Minamisono T, Fujii H, Morita T, Akamatsu A: Studies on the effects of hemodialysis on plasma lipoproteins. Trans Am Soc Artif Intern Organs 21:464-472, 1975
63. Joven J, Vilella E, Ahmad S, Cheung MC, Brunzell JD: Lipoprotein heterogeneity in end-stage renal disease. Kidney Int 43:410-418, 1993
64. Chan PCK, Persaud J, Varghese Z, Kingstone D, Baillod RA, Moorhead JF: Apolipoprotein B turnover in dialysis patients: Its relationship to pathogenesis of hyperlipidemia. Clin Nephrol 31:88-95, 1989
65. Horkko S, Huttunen K, Kesaniemi YA: Decreased clearance of low-density lipoprotein in uremic patients under dialysis treatment. Kidney Int 47:1732-1740, 1995
66. Hahn R, Oette K, Mondorf H, Finke K, Sieberth HG: Analysis of cardiovascular risk factors in chronic hemodialysis patients with special attention to the hyperlipoproteinemias. Atherosclerosis 48:279-288, 1983
67. Pedro-Botet J, Senti M, Rubies-Prat J, Pelegri A, Romero R: When to treat dyslipidaemia of patients with chronic renal failure on haemodialysis? A need to define specific guidelines [see comments]. Nephrol Dial Transplant 11:308-313, 1996
68. Cressman MD, Heyka RJ, Paganini EP, O'Neil J, Skibinski CI, Hoff HF: Lipoprotein(a) is an independent risk factor for cardiovascular disease in hemodialysis patients. Circulation 86:475-482, 1992
69. Docci D, Manzoni G, Baldrati L, Capponcini C, Neri L, Feletti C: Serum lipoprotein(a) as an independent cardiovascular risk factor for patients undergoing chronic hemodialysis. Nephron 69:195-195, 1995
70. Shoji T, Nishizawa Y, Nishitani H, Yamakawa M, Morii H: High serum lipoprotein(a) concentrations in uremic patients treated with continuous ambulatory peritoneal dialysis. Clin Nephrol 38:271-276, 1992
71. Dieplinger H, Lackner C, Kronenberg F, Sandholzer C, Lhotta K, Hoppichler F, Graf H, König P: Elevated plasma concentrations of lipoprotein(a) in patients with end-stage renal disease are not related to the size polymorphism of apolipoprotein(a). J Clin Invest 91:397-401, 1993
72. Kronenberg F, König P, Neyer U, Auinger M, Pribasnig A, Lang U, Reitinger J, Pinter G, Utermann G, Dieplinger H, Konig P: Multicenter study of liporpotein(a) and apolipoprotein(a) phenotypes in patients with end-stage renal disease treated by hemodialysis or continuous ambulatory peritoneal dialysis Multicenter study of lipoprotein(a) and apolipoprotein(a) phenotypes in patients with end-stage renal disease treated by hemodialysis or continuous ambulatory peritoneal dialysis. J Am Soc Nephrol 6:110-120, 1995
73. Massy ZA, Bader CA, Chevalier A, Chauveau P, Zingraft J, Lambrey G, Drueke T, Jungers P, Kreis H, Lacour B: Serum lipoprotein (a) levels in chronic renal failure and renal transplant patients. J Nephrol 7:229-236, 1994
74. Hernandez E, Praga M, Alamo C, Araque A, Morales JM, Alcazar JM, Ruilope LM, Rodicio JL: Lipoprotein(a) and vascular access survival in patients on chronic hemodialysis. Nephron 72:145-149, 1996
75. Yang WS, Kim SB, Min WK, Park S, Lee MS, Park JS: Atherogenic lipid profile and lipoprotein(a) in relation to serum albumin in haemodialysis patients. Nephrol Dial Transplant 10:1668-1671, 1995
76. Heimbürger O, Stenvinkel P, Berglund L, Tranoeus A, Lindholm B: Increased plasma lipoprotein(a) in continuous ambulatory peritoneal dialysis is related to peritoneal transport of proteins and glucose. Nephron 72:135-144, 1996
77. Okura Y, Saku K, Hirata K, Zhang B, Liu R, Ogahara SNS, Kajiyama G, Arakawa K: Serum lipoprotein(a) levels in maintenance hemodialysis patients. Nephron 65:46-50, 1993
78. Kates DM, Haas L, Brunzell J, Sherrard DJ: Risk factors for CVD in end-stage renal failure patients: A 21 year study. J Am Soc Nephrol 6:540-540, 1995 (abstr)
79. Koch M, Kutkuhn B, Trenkwalder E, Bach D, Grabensee B, Dieplinger H, Kronenberg F: Apolipoprotein B, fibrinogen, HDL cholesterol, and apolipoprotein(a) phenotypes predict CAD in hemodialysis patients. J Am Soc Nephrol 8:1889-1898, 1997
80. Manske CL, Wilson RF, Wang Y, Thomas W: Prevalence of, and risk factors for, angiographically determined CAD in type I-diabetic patients with nephropathy. Arch Intern Med 152:2450-2455, 1992
81. Koch M, Kutkuhn B, Grabensee B, Ritz E: Apolipoprotein A, fibrinogen, age, and history of stroke are predictors of death in dialysed diabetic patients: A prospective study in 412 subjects. Nephrol Dial Transplant 12:2603-2611, 1997
82. Degoulet P, Legrain M, Rëach I, Aimë F, Devriës C, Rojas P, Jacobs C: Mortality risk factors in patients treated by chronic hemodialysis. Report of the Diaphane collaborative study. Nephron 31:103-110, 1982
83. Kronenberg F, Kathrein H, König P, Neyer U, Sturm W, Lhotta K, Gröchenig E, Utermann G, Dieplinger H: Apolipoprotein(a) phenotypes predict the risk for carotid atherosclerosis in patients with end-stage renal disease. Arterioscler Thromb 14:1405-1411, 1994
84. del Cura J, Gil-Paraiso A, Borque L, Carazo M-E, Sanchez-Casajus A: Lipoprotein(a) in chronic renal failure patients undergoing hemodialysis: Does it have an independent role in the development of further cardiovascular complications? Nephron 65:644-645, 1993
85. Sniderman A, Cianflone K, Kwiterovich PO, Hutchinson T, Barre P, Prichard S: Hyperapobetalipoproteinemia: The major dyslipoproteinemia in patients with chronic renal failure treated with chronic ambulatory peritoneal dialysis. Atherosclerosis 565:257-264, 1987
86. Kagan A, Bar-Khayim Y, Schafer Z, Fainaru M: Kinetics of peritoneal protein loss during CAPD: II. Lipoprotein leakage and its impact on plasma lipid levels. Kidney Int 37:980-990, 1990
87. Staprans I, Piel CF, Felts JM: Analysis of selected plasma constituents in continuous ambulatory peritoneal dialysis effluent. Am J Kidney Dis 7:490-494, 1986
88. Querfeld U, LeBoeuf RC, Salusky IB, Nelson P, Laidlaw S, Fine RN: Lipoproteins in children treated with continuous peritoneal dialysis. Pediatr Res 29:155-159, 1991
89. Saku K, Sasaki J, Naito S, Arakawa K: Lipoprotein and apolipoprotein losses during continuous ambulatory peritoneal dialysis. Nephron 51:220-224, 1989
90. Cocchi R, Viglino G, Cancarini G, Catizone L, Favazza A, Tommasi A, Salomone M, Segoloni GP, Torpia R, Giangrande A: Prevalence of hyperlipidemia in a cohort of CAPD patients. Miner Electrolyte Metab 22:22-25, 1996
91. Gokal R, Ramos JM, McGurk JG, Ward MK, Kerr DNS: Hyperlipidemia in patients on continuous ambulatory peritoneal dialysis in Gahl GM, Kessel M, Nolph KD (eds): Advances in Peritoneal Dialysis. Proceedings of the Second International Symposium on Peritoneal Dialysis. Berlin, 1981. Princeton, NJ, Excerpta Medica, 1981
92. Webb AT, Brown EA: Prevalence of symptomatic arterial disease and risk factors for its development in patients on continuous ambulatory peritoneal dialysis. Perit Dial Int 13:S406-S408, 1993 (suppl 2)
93. Gault MH, Longerich L, Prabhakaran V, Purchase L: Ischemic heart disease, serum cholesterol, and apolipoproteins in CAPD. ASAIO Trans 37:M513-M514, 1991
94. Tsakiris D, Caslake MJ, Briggs JD, Packard CJ, Shepherd J: Low-density lipoprotein metabolism following renal transplantation. Transplantation 39:458-460, 1985
95. Chan MK, Persaud JW, Varghese Z, Fernando ON, Moorhead JF: Fat clearances and hyperlipidaemia in renal allograft recipients - The role of insulin resistance. Clin Chim Acta 114:61-67, 1981
96. Ghanem H, van den Dorpel MA, Weimar W, Man in 't Veld AJ, El-kannishy MH, Jansen H: Increased low density lipoprotein oxidation in stable kidney transplant recipients. Kidney Int 49:488-493, 1996
97. Aakhus S, Dahl K, Wideroe TE: Hyperlipidaemia in renal transplant patients. J Intern Med 239:407-415, 1996
98. Brown JH, Murphy BG, Douglas AF, Short CD, Bhatnagar D, Mackness MI, Doherty CC, Durrington PN: Influence of immunosuppressive therapy on lipoprotein(a) and other lipoproteins following renal transplantation. Nephron 75:277-282, 1997
99. Sugahara S, Koyama I, Yoshikawa Y, Dohi Y, Omoto R: Lipid and lipoprotein(a) in renal transplant recipients. Transplant Proc 26:2080-2081, 1994
100. Sharma AK, Myers TA, Hunninghake DB, Matas AJ, Kashtan CE: Hyperlipidemia in long-term suvivors of pediatric renal transplantation. Clin Transplantation 8:252-257, 1994
101. Nicholls AJ, Cumming AM, Catto GRD, Edward N, Engeset J: Lipid relationships in dialysis and renal transplant patients. Q J Med 50:149-160, 1981
102. Chatterjee SN, Chin HP, Azen SP, Blankenhorn DH, Boothe S, Massry SG: Abnormal serum lipid patterns in primary renal allograft recipients. Surgery 82:655-659, 1977
103. Goldberg RB, Judelman JJ, Mindel A, Meyers AM, Salant DJ, Myburgh JA, Rabkin R, Joffe BI, Seftel HC: Hyperlipidaemia in renal transplant patients. S Afr Med J 50:1291-1294, 1976
104. Segarra A, Chacón P, Martin M, Vilardell M, Vila J, Cotrina M, Fort J, Olmos A, Piera LL, Chacon P: Serum lipoprotein (a) levels in patients with chronic renal failure - Evolution after renal transplantation and relationship with other parameters of lipoprotein metabolism: A prospective study. Nephron 69:9-13, 1995
105. Webb AT, Reaveley DA, O'Donnell M, O'Connor B, Seed M, Brown EA: Does cyclosporin increase lipoprotein(a) concentrations in renal transplant recipients? Lancet 341:268-270, 1993
106. Heule H, Keusch G, Uhlschmid G, Largiadèr F, Binswanger U: Kardiovasculäre Krankheiten nach Nieren-transplantation: eine Analyse prädisponierender Facktoren. Schweiz Med Wochenschr 20:709-716, 1981
107. Abdulmassih Z, Chevalier A, Bader C, Drüeke T, Kreis H, Lacour B: Role of lipid disturbances in the atherosclerosis of renal transplant patients. Clin Transplant 6:106-113, 1992
108. Kasiske BL: Risk factors for accelerated atherosclerosis in renal transplant recipients. Am J Med 84:985-992, 1988
109. Kasiske BL, Guijarro C, Massy ZA, Weiderkehr MR, Ma JZ: CVD after renal transplantation. J Am Soc Nephrol 7:158-165, 1996
110. Dimény E, Tufveson G, Lithell H, Larsson E, Siegbahn A, Fellström B: The influence of pretransplant lipoprotein abnormalities on the early results of renal transplantation. Eur J Clin Invest 23:572-579, 1993
111. Dimény E, Fellström B, Larsson E, Tufveson G, Lithell H: Chronic vascular rejection and hyperlipoproteinemia in renal transplant patients. Clin Transplant 7:482-490, 1993
112. Isoniemi H, Nurminen M, Tikkanen M, von Willebrand E, Krogerus L, Ahonen J, Eklund B, Höckerstedt K, Salmela K, Häyry P, Tikkanen MJ, Hockerstedt K, Hayry P: Risk factors predicting chronic rejection of renal allograft. Transplantation 57:68-72, 1994
113. Massy ZA, Guijarro C, Wiederkehr MR, Ma JZ, Kasiske BL: Chronic renal allograft rejection: immunologic and nonimmunologic risk factors. Kidney Int 49:518-524, 1996
114. Jensen RA, Lal SM, Diaz-Arias A, James-Kracke M, Van Stone JC, Ross G Jr: Does cholestyramine interfere with cyclosporine absorption? A prospective study in renal transplant patients. ASAIO J 41:M704-M706, 1995
115. The Expert Panel: Report of the national cholesterol education program expert panel on detection, evaluation and treatment of high blood cholesterol in adults. Arch Intern Med 148:36-69, 1988
116. Schaefer EJ, Wilson PW, Castelli WP, Ordovas JM, Schaefer MM, Cohn SD, Lamon-Fava S: Effects of age, gender, and menopausal status on plasma low density lipoprotein cholesterol and apolipoprotein B levels in the Framingham Offspring Study. J Lipid Res 35:779-792, 1994
117. Kasiske BL: Management of lipid abnormalities in patients with renal disease, in Mitch WE, Klahr S (eds): Handbook of Nutrition and the Kidney. Philadelphia, PA, Lippincott-Raven, 1998, pp 123-143